BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 13, 2024
Home
»
Newsletters
» BioWorld
BioWorld
July 14, 2009
View Archived Issues
Tarceva Survival Data Intensify Lung Cancer Maintenance Battle
It's been barely a week since Eli Lilly and Co.'s chemotherapy drug Alimta (pemetrexed) received the first-ever FDA approval in the maintenance treatment of lung cancer, and already the competition is closing in. (BioWorld Today)
Read More
Antiplatelet Space Growing, Plavix Still Strong - for Now
Read More
Mixed News on H1N1 Emerges from WHO and Nature Study
Read More
NewCo News: Cardioxyl's Nitroxyl Donor Drug Starts Testing in Heart Failure
Read More
HHS Piles on Swine Flu Money: $884M More for H1N1 Vaccine
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Financings Roundup
Read More